ABVC Biopharma Inc

ABVC13 Dec 2024
Healthcare
$0.49
-0.06 (-6.37%)
Lowest Today
$0.47
Highest Today
$0.49
Today’s Open
$0.49
Prev. Close
$0.52
52 Week High
$2.45
52 Week Low
$0.41
To Invest in ABVC Biopharma Inc

ABVC Biopharma Inc

Healthcare
ABVC13 Dec 2024
-0.06 (-6.37%)
1M
3M
6M
1Y
5Y
Low
$0.47
Day’s Range
High
$0.49
0.47
52 Week Low
$0.41
52-Week Range
52 Week High
$2.45
0.41
1 Day
-
1 Week
-
1 month return
-6.54%
3 month return
-27.56%
6 month return
-40.45%
1 Year return
-54.95%
3 Years return
-98.36%
5 Years return
-
10 Years return
-
Institutional Holdings
Geode Capital Management, LLC
0.58
Fidelity Extended Market Index
0.43
Vanguard Group Inc
0.38
Vanguard Institutional Extnd Mkt Idx Tr
0.38
Honkamp Krueger Financial Services Inc
0.32
XTX Topco Ltd
0.19
Northern Trust Corp
0.16

Market Status

Fundamentals
Market Cap
6.36 mln
PB Ratio
0.7
PE Ratio
0
Enterprise Value
7.93 mln
Total Assets
14.49 mln
Volume

Company Financials

Fund house & investment objective

Company Information
ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.
Organisation
ABVC Biopharma Inc
Employees
16
Industry
Biotechnology
CEO
Dr. Uttam Yashwant Patil Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities